Related Experiment Video

Updated: Aug 29, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588

Philipp le Coutre1, Karl-Anton Kreuzer, Stefan Pursche

  • 1Medizinische Klinik für Hämatologie und Onkologie, Campus Virchow, Charité, Humboldt Universität Berlin, Germany.

Cancer Chemotherapy and Pharmacology
|December 6, 2003
PubMed

Insights

This study details imatinib pharmacokinetics in leukemia patients, revealing key data on drug levels, its metabolite, and limited blood-brain barrier penetration. These findings aid in understanding imatinib resistance and response variations.

Area of Science:

  • Pharmacology
  • Oncology
  • Biochemistry

Background:

  • Imatinib is effective for bcr-abl leukemias, but pharmacokinetic data are limited.
  • Understanding imatinib pharmacokinetics is crucial for addressing resistance and interindividual response variations.
  • The role of the metabolite N-desmethyl-imatinib requires further investigation.

Purpose of the Study:

  • To characterize the pharmacokinetics of imatinib and its metabolite N-desmethyl-imatinib in leukemia patients.
  • To assess imatinib penetration into the cerebrospinal fluid (CSF).
  • To determine in vitro cellular uptake of imatinib.

Main Methods:

  • High-performance liquid chromatography (HPLC) was used to analyze imatinib and N-desmethyl-imatinib plasma concentrations.
  • Pharmacokinetic parameters including AUC, t(1/2), and peak concentration were calculated.
  • In vitro studies assessed imatinib cellular uptake in HL-60 cells.

Main Results:

  • Calculated imatinib AUC (39.5 microg.h/ml), t(1/2) (18.2 h), and peak concentration (1.92 micro/ml) for a 400 mg daily dose.
  • N-desmethyl-imatinib pharmacokinetic parameters were analyzed in a patient subgroup.
  • Oral imatinib showed minimal penetration into the CSF, and in vitro studies indicated significant cellular uptake.

Conclusions:

  • This study provides essential pharmacokinetic data for imatinib and its primary metabolite.
  • Limited CSF penetration suggests challenges in treating central nervous system leukemia with oral imatinib.
  • The findings contribute to a better understanding of imatinib's behavior in vivo and in vitro.

More Related Videos

Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-794109:50

Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941

Published on: April 28, 2019

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...